SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Myron David Kor who wrote (2441)2/20/1998 4:48:00 PM
From: Linda Kaplan  Read Replies (1) of 7041
 
Myron,

There's no reason I can see for Ms. Feldman to come to SI to satisfy us. It is her job to write reports for Wessels and she is accountable to the company for whom she works and their clients. Why should she get into a catfight with stockholders of a company on which she is reporting?

Like Brad Anderson suggested, I'd like to see the full research from Zonagen. They have completed studies but where is the reports from them? VVUS had studies in the New England Journal of Medicine, and reports available in detail about their studies. If Zonagen disputes the findings of Ms. Feldman, when will they produce detailed reports of their Phase II and III studies? Have they produced them already? Has anyone seen them?

Linda
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News